Investigating as a Novel Biomarker Correlated With the Development and Poor Prognosis of Breast Carcinoma.

Breast invasive carcinoma (BRCA) is a carcinoma with a fairly high incidence, and the therapeutic schedules are generally surgery and chemotherapy. However, chemotherapeutic drugs tend to produce serious toxic side effects, which lead to the cessation of treatment. Therefore, it is imperative to develop treatment strategies that are more effective and have fewer side effects at the genetic level. Centromeric protein W () is an oncogene that plays an important part in nucleosome assembly. To date, no studies have reported the prognostic significance of in breast carcinoma. In this study, we verified that expression is up-regulated in breast carcinoma and positively associated with the level of immune cell infiltration. The clinicopathological characteristics further suggest that expression is correlated with a worse prognosis of breast carcinoma. Interestingly, the mutation contributes to the poor prognosis. Next, we discovered that the genes interacting with are mainly concentrated in the cell cycle pathway, and is co-expressed with , which is also highly expressed in breast carcinoma and leads to a worse prognosis. Our subsequent studies verified that knockdown of significantly inhibits the proliferation and migration of breast carcinoma cells and promotes their apoptosis rate. Notably, inhibition of CEMPW sensitizes breast cancer cells to chemotherapeutic drugs that have been found to induce cell cycle arrest. In summary, these results provide extensive data and experimental evidence that can serve as a novel predictor of breast cancer and may act as a prospective therapeutic target.